BRPI0510775A - biomarcadores para a previsão da reação ao tratamento com clozapina - Google Patents

biomarcadores para a previsão da reação ao tratamento com clozapina

Info

Publication number
BRPI0510775A
BRPI0510775A BRPI0510775-0A BRPI0510775A BRPI0510775A BR PI0510775 A BRPI0510775 A BR PI0510775A BR PI0510775 A BRPI0510775 A BR PI0510775A BR PI0510775 A BRPI0510775 A BR PI0510775A
Authority
BR
Brazil
Prior art keywords
biomarkers
treatment
clozapine
reaction
slc6a3
Prior art date
Application number
BRPI0510775-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Yunsheng He
Elisabeth Marie Leroy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0510775A publication Critical patent/BRPI0510775A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0510775-0A 2004-06-04 2005-06-03 biomarcadores para a previsão da reação ao tratamento com clozapina BRPI0510775A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57713104P 2004-06-04 2004-06-04
PCT/EP2005/006002 WO2005118848A1 (en) 2004-06-04 2005-06-03 Biomarkers for the prediction of responsiveness to clozapine treatment

Publications (1)

Publication Number Publication Date
BRPI0510775A true BRPI0510775A (pt) 2007-11-20

Family

ID=34970966

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510775-0A BRPI0510775A (pt) 2004-06-04 2005-06-03 biomarcadores para a previsão da reação ao tratamento com clozapina

Country Status (10)

Country Link
US (1) US20090281090A1 (enExample)
EP (1) EP1756314A1 (enExample)
JP (1) JP2008505060A (enExample)
CN (1) CN1973051A (enExample)
AU (1) AU2005250142B2 (enExample)
BR (1) BRPI0510775A (enExample)
CA (1) CA2568729A1 (enExample)
MX (1) MXPA06014127A (enExample)
RU (1) RU2006146207A (enExample)
WO (1) WO2005118848A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136996A2 (en) * 2007-04-30 2008-11-13 The Ohio State University Research Foundation Polymorphisms in genes affecting ace-related disorders and uses thereof
US7932042B1 (en) 2010-10-13 2011-04-26 Suregene, Llc Methods and compositions for the treatment of psychotic disorders through the identification of the olanzapine poor response predictor genetic signature
US20130029862A1 (en) * 2011-06-02 2013-01-31 Gareth Davies Clinical application utilizing genetic data for effective medication management
EP2883052B8 (en) 2012-08-10 2019-03-13 Istituto Superiore di Sanità Biomarkers
CN112195230B (zh) * 2020-09-17 2022-08-23 青岛大学附属医院 一种用于氯氮平个体化用药指导的基因检测试剂、试剂盒、检测方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2381525A (en) * 2001-11-01 2003-05-07 Tcs Cellworks Ltd Regulating gene expression
AU2003207989A1 (en) * 2002-02-21 2003-09-09 Idgene Pharmaceuticals Ltd. Association of snps in the comt locus and neighboring loci with schizophrenia, bipolar disorder, breast cancer and colorectal cancer
WO2003101377A2 (en) * 2002-06-03 2003-12-11 Idgene Pharmaceuticals Ltd. Association of snps in the dgcr2 locus and neighboring loci with schizophrenia
WO2004074513A1 (en) * 2003-02-21 2004-09-02 Novartis Ag Methods for the prediction of suicidality during treatment

Also Published As

Publication number Publication date
AU2005250142A1 (en) 2005-12-15
MXPA06014127A (es) 2007-01-31
CN1973051A (zh) 2007-05-30
AU2005250142B2 (en) 2008-08-21
US20090281090A1 (en) 2009-11-12
WO2005118848A1 (en) 2005-12-15
EP1756314A1 (en) 2007-02-28
JP2008505060A (ja) 2008-02-21
CA2568729A1 (en) 2005-12-15
RU2006146207A (ru) 2008-07-20

Similar Documents

Publication Publication Date Title
Meder et al. Epigenome-wide association study identifies cardiac gene patterning and a novel class of biomarkers for heart failure
Krakau et al. PureCLIP: capturing target-specific protein–RNA interaction footprints from single-nucleotide CLIP-seq data
JP7295092B2 (ja) 結合試薬を選択する方法
WO2008063479A3 (en) Pancreatic cancer biomarkers
Suzuki et al. Aberrant methylation of microRNA-34b/c is a predictive marker of metachronous gastric cancer risk
NO20080371L (no) Fremgangsmate for a forutsi responsen overfor en behandling
BRPI0715126B8 (pt) métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15
DE602007013524D1 (de) Erkennung und vorhersage von frühgeburten
JP2015505370A5 (enExample)
WO2008132176A3 (en) Method for evaluating the response of an individual to tnf blocking therapy
EP2253713A4 (en) METHOD FOR MEASURING COPY COUNTS OF CHROMOSOMES, GENES OR SPECIFIC NUCLEOTIDE SEQUENCES WITH THE AID OF AN SNP ARRAY
JP2017503527A5 (enExample)
EP2021512A4 (en) SYSTEMS AND METHODS FOR DEVELOPING DIAGNOSTIC TESTS BASED ON BIOMARKER INFORMATION FROM SURGICAL CLINICAL SAMPLES
JP2009515553A5 (enExample)
DE602006020544D1 (de) Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs
WO2008048508A3 (en) Prognostic biomarkers in patients with ovarian cancer
BRPI0510775A (pt) biomarcadores para a previsão da reação ao tratamento com clozapina
WO2008011620A3 (en) Methods and nucleic acids for analyses of cellular proliferative disorders
MXPA05008793A (es) Metodos para la prediccion de posibilidad de suicidio durante el tratamiento.
Chu et al. Comparison of RNA isolation and library preparation methods for small RNA sequencing of canine biofluids
NZ593392A (en) Biomarker for detecting bladder cancer
Dick et al. Chemical links between redox conditions and estimated community proteomes from 16S rRNA and reference protein sequences
WO2009141352A3 (en) Risk analysis in patients with and without metabolic syndrome
WO2009125936A3 (ko) 다낭성 난소 증후군 진단을 위한 분석방법 및 키트
Lazaryan et al. Evolving concepts in prognostic scoring of chronic GvHD

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.